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a b s t r a c t
Key challenges faced by all cells include how to spatiotemporally organize complex biochemistry and how
to respond to environmental ﬂuctuations. The budding yeast Saccharomyces cerevisiae harnesses alternative
protein folding mediated by yeast prion domains (PrDs) for rapid evolution of new traits in response to
environmental stress. Increasingly, it is appreciated that low complexity domains similar in amino acid
composition to yeast PrDs (prion-like domains; PrLDs) found in metazoa have a prominent role in sub-
cellular cytoplasmic organization, especially in relation to RNA homeostasis. In this review, we highlight
recent advances in our understanding of the role of prions in enabling rapid adaptation to environmental
stress in yeast. We also present the complete list of human proteins with PrLDs and discuss the prevalence
of the PrLD in nucleic-acid binding proteins that are often connected to neurodegenerative disease, in-
cluding: ataxin 1, ataxin 2, FUS, TDP-43, TAF15, EWSR1, hnRNPA1, and hnRNPA2. Recent paradigm-shifting
advances establish that PrLDs undergo phase transitions to liquid states, which contribute to the structure
and biophysics of diverse membraneless organelles. This structural functionality of PrLDs, however, si-
multaneously increases their propensity for deleterious protein-misfolding events that drive neurodegen-
erative disease. We suggest that even these PrLD-misfolding events are not irreversible and can be mitigated
by natural or engineered protein disaggregases, which could have important therapeutic applications.
This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Prions as epigenetic regulators in yeast
Alternative protein folding underpins prion-based phenomena
(Lindquist, 1997; Prusiner, 1998; Shorter, 2010). Prions are in-
fectious proteins that can adopt many functionally distinct con-
formations, at least one of which is self-replicating (Prusiner, 1998;
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Shorter, 2010). Whereas the mammalian prion protein (PrP) forms
prions that cause devastating neurodegenerative diseases (Aguzzi
and Lakkaraju, 2016; Colby and Prusiner, 2011; Collinge and Clarke,
2007; Ma and Wang, 2014), prions in yeast are often benign and
can even confer selective advantages (Liebman and Chernoff,
2012; Lindquist, 1997; Newby and Lindquist, 2013; Shorter and
Lindquist, 2005; Suzuki et al., 2012; True and Lindquist, 2000).
Amyloid ﬁbril formation is a unifying feature of both mammalian
and fungal prion phenomena, and indeed underpins several age-
related neurodegenerative diseases including Alzheimer's disease
and Parkinson's disease (Colby and Prusiner, 2011; Cushman et al.,
2010; Guo and Lee, 2014; Shorter and Lindquist, 2005). Thus, un-
derstanding key determinants of this basic biophysical process as
it relates to yeast prions will help illuminate new therapeutic
strategies for human disease.
The yeast prion states, [PSIþ] and [URE3], are embodied by self-
replicating conformers of their protein determinants Sup35 and
Ure2, respectively (Cox, 1965; Tuite and Serio, 2010; Tuite et al.,
2015; Wickner, 1994). Sup35 is a translation termination factor in
yeast; the yeast prion state [PSIþ] is associated with a nonsense
suppression phenotype (Tuite et al., 2015). Prion-switching beha-
vior of Sup35 can be readily assessed in yeast harboring a pre-
mature stop codon in their ADE1 gene: [psi] cells (which lack
Sup35 prions) are red on rich media and require adenine whereas
[PSIþ] cells appear white on rich media and can grow on media
lacking adenine (Tuite et al., 2015).
Yeast prion formation is typically mediated by modular and
transferable prion domains (PrDs), which are low complexity se-
quences enriched in polar, uncharged amino acids such as gluta-
mine, asparagine, tyrosine, and serine as well as glycine (Alberti
et al., 2009; An et al., 2016; Edskes et al., 1999; Li and Lindquist,
2000; Michelitsch and Weissman, 2000; Santoso et al., 2000;
Sondheimer and Lindquist, 2000). An exception is found in Mod5,
which forms beneﬁcial [MODþ] prions without a canonical PrD,
and instead harbors an amyloid core-forming region enriched in
hydrophobic residues (Suzuki and Tanaka, 2013). Importantly,
deletion of the PrD from Sup35 and Ure2 does not affect normal
protein function (Coschigano and Magasanik, 1991; Ter-Avanesyan
et al., 1993). Conversely, PrDs can be appended to model proteins
to generate novel engineered prions (Alberti et al., 2009; Li and
Lindquist, 2000; Osherovich and Weissman, 2001; Tyedmers et al.,
2010). Furthermore, the sequence of the PrD can be scrambled and
still encode prion behavior (Ross et al., 2004, 2005). Thus, it is the
amino acid composition and not the exact primary sequence of a
PrD, which is critical for prionogenesis (Ross et al., 2004, 2005).
The modular, transferable, and randomizable nature of PrDs has
proven enormously instructive in the quest to discover novel
prions. A hidden Markov model, based on the amino acid com-
position of PrDs of Sup35, Ure2, and Rnq1, was developed to query
the S. cerevisiae genome for novel prions (Alberti et al., 2009),
yielding 200 candidates (cPrDs). To characterize these, chimeras
consisting of cPrDs fused to the C-terminal domain of Sup35 were
expressed in yeast and cPrDs were assessed based on their ability
to mimic the [PSIþ] phenotype (e.g. red-white colony color
switching) (Alberti et al., 2009). Further reﬁnement of cPrDs by
biochemical and yeast phenotypic analysis led to the discovery of
Mot3 prions (Alberti et al., 2009; Holmes et al., 2013). Importantly,
not all cPrDs conferred prion behavior (Alberti et al., 2009), and
subsequent algorithms have been used as ﬁlters to improve pre-
diction accuracy and even to design PrDs capable of bona ﬁde
prionogenesis (Paul et al., 2015; Toombs et al., 2010, 2012).
[MOT3þ] is a prion state formed by self-replicating conformers
of its protein determinant, Mot3 (Alberti et al., 2009; Halfmann
et al., 2012). Mot3 is a transcription factor that modulates a variety
of processes including mating, carbon metabolism, and stress re-
sponse by repressing anaerobic genes such as DAN1 during aerobic
growth (Grishin et al., 1998). Perhaps most importantly, [MOT3þ]
governs the acquisition of multicellular growth phenotypes in
yeast through transcriptional regulation of FLO11 (Holmes et al.,
2013). [MOT3þ] enables acquisition of facultative multicellular
growth phenotypes including invasive growth on poor nitrogen
sources, complex colony morphology as a starvation response, and
ﬂocculation in liquid media (Holmes et al., 2013). Furthermore,
similar results were found in wild strains harboring [MOT3þ]
(Halfmann et al., 2012). These ﬁndings illustrate the potential of
prions to facilitate rapid adaptation to environmental cues (Lind-
quist, 1997; Shorter and Lindquist, 2005).
Yeast prions can confer selective advantages in various cir-
cumstances, but can also be neutral or detrimental in other set-
tings (Du et al., 2015; Halfmann et al., 2012; Holmes et al., 2013;
Newby and Lindquist, 2013; Shorter and Lindquist, 2005; Suzuki
et al., 2012; Wickner et al., 2011). The beneﬁcial phenotypes con-
ferred by yeast prions are often observed under stress conditions,
which has led to the suggestion that yeast prions constitute bet-
hedging devices, which can reveal potentially adaptive genetic
diversity in ﬂuctuating environments (Du et al., 2015; Garcia and
Jarosz, 2014; Halfmann et al., 2010; Halfmann and Lindquist, 2010;
Masel and Bergman, 2003; Newby and Lindquist, 2013; Tyedmers
et al., 2008). This process is facilitated by the conformational range
of PrDs, which can access multiple, distinct cross-β structures or
strains (Shorter, 2010). Moreover, protein folding is exquisitely
sensitive to environment, allowing even subtle changes to favor
one conformation, and therefore one function, over another
(Halfmann et al., 2010, 2012; Halfmann and Lindquist, 2010;
Holmes et al., 2013). In the case of Sup35 prions, [PSIþ]-mediated
stop codon read-through allows expression of cryptic genetic
variation that accumulates in 3′ untranslated regions at many ge-
netic loci (Baudin-Baillieu et al., 2014; Halfmann et al., 2012; Namy
et al., 2008; True and Lindquist, 2000; True et al., 2004). Indeed,
Sup35 prions act as evolutionary capacitors that release cryptic
genetic variation under stress to facilitate the rapid evolution of
adaptive traits (Masel and Siegal, 2009; Shorter and Lindquist,
2005).
The adaptive signiﬁcance of yeast prions, particularly Sup35
prions, has been contested (McGlinchey et al., 2011; Nakayashiki
et al., 2005; Wickner et al., 2011, 2015). There has been a lack of
evidence that Sup35 and Ure2 prions arise in wild yeast (although
Rnq1 prions were readily found) (Chernoff et al., 2000; Resende
et al., 2003), leading to speculation that prions were merely 'dis-
eases’ or artifacts of laboratory cultivation (Wickner et al., 2011,
2015). However, a survey of 690 wild yeast strains from diverse
biological niches found 10 strains harboring Sup35 prions, 43
harboring Rnq1 prions, and 6 harboring Mot3 prions (Halfmann
et al., 2012). Prions conferred a range of phenotypes that increased
ﬁtness of these yeast strains under a wide variety of stresses, and
the prion phenotypes could become genetically ﬁxed, thus ful-
ﬁlling key predictions for bet-hedging prions (Halfmann et al.,
2012). However, several of the advantageous [PSIþ]-dependent
phenotypes of wild yeast strains were not replicated in another
study (Wickner et al., 2015). Nonetheless, the preponderance of
evidence suggests that yeast prion proteins undergo en-
vironmentally-sensitive, alternative folding to effect epigenetic
changes that increase ﬁtness in response to ﬂuctuating environ-
ments (Garcia and Jarosz, 2014; Halfmann et al., 2012; Newby and
Lindquist, 2013; Suzuki et al., 2012).
2. Prion-like domains in humans
Do human proteins contain domains similar in amino acid
composition to yeast PrDs? We applied an updated PrD detection
algorithm, PLAAC (for Prion-Like Amino Acid Composition, with
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default core length of 60 and alpha set to 0.5) (Lancaster et al.,
2014), to the human genome (Ensembl GRCh38.p5, release 83) and
uncovered 240 genes out of 20,000 protein-coding genes
(1.2%) harboring a domain compositionally similar to annotated
yeast PrDs, termed a prion-like domain (PrLD) (Couthouis et al.,
2011; Cushman et al., 2010; Kim et al., 2013; King et al., 2012;
Lancaster et al., 2014; Li et al., 2013). The complete list of human
proteins with a PrLD, including the location of each PrLD, is pre-
sented in Table S1. Remarkably, 72/240 (30%) of these proteins are
annotated with the gene ontology (GO) molecular function “RNA
binding” and 79/240 (33%) with the GO molecular function “DNA
binding” (Table 1). These are among the nine terms from the
generic GO slim (an abridged versions of the full gene ontology)
that are signiﬁcantly enriched for human PrLD-containing proteins
(Fisher's exact test, with Holm's adjusted po0.05); the others are
molecular functions “transcription factor activity, protein binding,”
“nucleic acid binding transcription factor activity,” and “transcrip-
tion factor binding”; biological processes “chromosome organiza-
tion”, “mRNA processing,” and cellular components “nucleoplasm”
and 'nucleolus' (Table 1); 174/240 (73%) of human PrLD-con-
taining proteins were annotated in at least one of these categories
(Fig. 1). There are also three GO Slim categories in which PrLD-
containing proteins are signiﬁcantly underrepresented: molecular
functions “signal transducer activity” and cellular components
“plasma membrane” and “mitochondrion” (Table 1). Our ﬁndings
suggest that RNA-binding proteins (RBPs) and DNA-binding pro-
teins that reside primarily in the nucleus are signiﬁcantly over-
represented among the collection of PrLD-containing human
proteins (King et al., 2012; Li et al., 2013). Thus, PrLDs feature
prominently at the critical functional interfaces between nucleic
acid and protein.
Several human RBPs with PrLDs including ataxin 1, ataxin 2,
TDP-43, FUS, TAF15, EWSR1, hnRNPA1, and hnRNPA2 (Table S1)
feature prominently in the pathology and genetics of a number of
fatal neurodegenerative diseases, including amyotrophic lateral
sclerosis (ALS), frontotemporal dementia (FTD), and spinocer-
eballar ataxias (Couthouis et al., 2011, 2012, 2014; Cushman et al.,
2010; Elden et al., 2010; Kim et al., 2013; Kwiatkowski et al., 2009;
Neumann et al., 2006; Orr and Zoghbi, 2007; Orr, 2012; Vance
et al., 2009; Zoghbi and Orr, 2009). For example, TDP-43 mis-
localizes from the nucleus to cytoplasmic inclusions in degen-
erating neurons in ALS and FTD, and is an intrinsically aggregation
prone protein (Johnson et al., 2009; Ling et al., 2013; Neumann
et al., 2006). The PrLD of TDP-43 confers this intrinsically
aggregation-prone property (Johnson et al., 2009). Almost all ALS-
and FTD-linked TDP-43 mutations lie in the PrLD, and several of
these mutations can promote deleterious TDP-43 misfolding and
enhance proteotoxicity in diverse model systems (Barmada et al.,
2010; Guo et al., 2011; Johnson et al., 2009; Kabashi et al., 2010; Li
et al., 2010; Lim et al., 2016; Ling et al., 2013; Ritson et al., 2010;
Sreedharan et al., 2008; Zhang et al., 2009). Likewise, multisystem
proteinopathy (MSP) can be caused by missense mutations in the
PrLD of hnRNPA1 or hnRNPA2 (Kim et al., 2013; Shorter and Taylor,
2013). These mutations alter a gatekeeper aspartate residue and
introduce a potent steric zipper motif into the PrLD, which accel-
erates formation of self-templating hnRNPA1 and hnRNPA2 ﬁbrils
(Kim et al., 2013; Shorter and Taylor, 2013). Furthermore, poly-
glutamine expansions in the PrLD of ataxin 1 cause spinocereballar
ataxia 1, and promote ataxin 1 aggregation (Banﬁ et al., 1994;
Cummings et al., 1998). These three striking examples and many
others (Chesi et al., 2013; Couthouis et al., 2011, 2012, 2014;
Hackman et al., 2013; Klar et al., 2013; Mori et al., 2013; Patel et al.,
2015; Vieira et al., 2014) suggest that human proteins with PrLDs
are prone to deleterious misfolding events that underpin neuro-
degenerative disease. Thus, special attention to these proteins is
urgently warranted. We suggest that human proteins bearing a
PrLD (Table 1) should be scrutinized as potential etiological agents
of various degenerative diseases, which might be revealed via gene
sequencing and histopathological examination of protein locali-
zation (King et al., 2012).
Do human proteins with PrLDs form bona ﬁde prions? Cur-
rently, there is no evidence that any human protein with a PrLD
can form a prion like PrP, which can naturally transmit devastating
neurodegenerative disease between individuals (Colby and Prusi-
ner, 2011; Collinge, 1999; Prusiner, 1998). Nonetheless, PrLDs do
enable proteins to spontaneously form self-templating ﬁbrils in
isolation (Kim et al., 2013). Intriguingly, ataxin 1 bearing a polyQ
expansion within the PrLD can form oligomeric structures that
induce local spread of ataxin 1 pathology in transgenic mice (La-
sagna-Reeves et al., 2015). Moreover, TDP-43 and TDP-43 frag-
ments containing the PrLD (193-414) can form ﬁbrils that elicit
TDP-43 aggregation in cell culture (Furukawa et al., 2011). Fur-
thermore, detergent-insoluble fractions from ALS brains contain
TDP-43 ﬁbrils and induce TDP-43 aggregation in cell culture
(Nonaka et al., 2013). Thus, TDP-43 may access a prion-like con-
formation, which may even be transmitted across axon terminals
(Feiler et al., 2015). Indeed, phosphorylated TDP-43 pathology in
ALS has been interpreted to spread in a sequential manner with
Table 1
Gene Ontology categories in which human PrLD-containing proteins are signiﬁcantly over- or under-represented. Fisher's exact test was used to test for independence
between the set of human proteins with PrLDs and GO Slim gene annotations for 129 categories (14 with fewer than 5 or more than 5000 annotated genes were excluded);
the categories with p-valueo0.05 after adjusting for multiple hypothesis testing with Holm's method are shown. Columns give the GO ID, branch of the ontology, GO term,
number of genes with this annotation overall (n.total) and among PrLD containing-proteins (n.PrLD), odds ratio, raw p-value, and Holm's-adjusted p-value. Only the longest
protein-coding transcript for each HUGO gene name was included in the analyses to avoid redundancies, and 906 genes with no GO Slim annotations (including 4 with
PrLDs) were excluded from the gene universe, as were those encoding proteins of fewer than 60 amino acids, leaving 18,672 genes in the universe, 236 of them with PrLDs.
GO.id GO.branch GO.term n.total n.PrLD Odds.ratio p.raw p.adjusted
Over-represented
GO:0005654 CC Nucleoplasm 2879 116 5.48 2.2e34 2.9e32
GO:0003723 MF RNA binding 1545 72 5.05 2.5e23 3.2e21
GO:0000988 MF Transcription factor activity, protein binding 516 37 6.97 8.8e18 1.1e15
GO:0003677 MF DNA binding 2320 79 3.64 2.3e17 2.9e15
GO:0006397 BP mRNA processing 430 31 6.83 4.4e15 5.4e13
GO:0051276 BP Chromosome organization 971 44 4.33 1.1e13 1.4e11
GO:0001071 MF Nucleic acid binding transcription factor activity 1077 39 3.32 2.5e09 3.1e07
GO:0008134 MF Transcription factor binding 432 16 3.15 1.3e04 1.6e02
GO:0005730 CC Nucleolus 810 23 2.42 2.8e04 3.4e02
Under-represented
GO:0005886 CC Plasma membrane 4539 23 0.33 1.6e08 1.9e06
GO:0004871 MF Signal transducer activity 1566 4 0.19 2.5e05 3.0e03
GO:0005739 CC Mitochondrion 1319 4 0.22 2.8e04 3.4e02
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highly discernible stages that might indicate involvement of ax-
onal pathways (Brettschneider et al., 2013, 2014; Ludolph and
Brettschneider, 2015). Prion-like conformers have been proposed
to underlie this spreading phenomenon in ALS and other disorders
(Cushman et al., 2010; Grad et al., 2015; King et al., 2012; Li et al.,
2013; Maniecka and Polymenidou, 2015; Polymenidou and Cle-
veland, 2011, 2012; Ravits and La Spada, 2009). Although intri-
guing, compelling proof of formation of prions will require their de
novo construction from purely synthetic protein and an ability to
infect wild-type mice with a neurodegenerative disease, as has
been achieved with PrP and α–synuclein (Luk et al., 2012; Wang
et al., 2010, 2011a, 2011b). Even then, only PrP has been shown to
form prions that can spread disease naturally between individuals
in a population (Colby and Prusiner, 2011; Collinge, 1999; Prusiner,
1998). Evidence is currently lacking that α–synuclein conformers
can be infectious in this way.
These various connections with neurodegenerative disease
have led to a negative view of PrLDs in human proteins (Cushman
et al., 2010; Gitler and Shorter, 2011; King et al., 2012; Li et al.,
2013). However, PrLDs are found in 240 human proteins, and so
presumably may serve some beneﬁcial or essential function. In-
deed, many genes that encode proteins containing PrLDs are es-
sential in mammals (Kraemer et al., 2010; Sephton et al., 2010;
Wang et al., 2015). Furthermore, unlike the PrDs of Sup35 and
Ure2, the PrLDs of several human proteins, including TDP-43,
hnRNPA1, and hnRNPA2 play a critical role in protein function (Li
et al., 2013). For example, the PrLD of TDP-43 is not required for
RNA- or DNA-binding activity, but is critical for alternative splicing
of some mRNAs and for protein-protein interactions with other
hnRNPs, including hnRNPA1, hnRNPA2, and FUS, as well compo-
nents of the Dicer and Drosha complexes (Ayala et al., 2005;
Buratti et al., 2005; D'Ambrogio et al., 2009; Kawahara and Mieda-
Sato, 2012; Kim et al., 2010). Likewise, the PrLDs of hnRNPA1 and
hnRNPA2 make important contributions to the splicing activity of
these proteins (Mayeda et al., 1994). Recent reports suggest that
PrLDs may have an important role in critical phase transition
events that provide organizational scaffolds for various membra-
neless organelles, including RNP granules and nuclear sub-
compartments (Brangwynne et al., 2015; Courchaine and Neuge-
bauer, 2015; Guo and Shorter, 2015; Hennig et al., 2015; Kawa-
guchi and Hirose, 2015; Li et al., 2013; Ramaswami et al., 2013).
3. Structure and function of membraneless cellular
compartments
In addition to classical membrane-delimited organelles, the
eukaryotic cell is also organized by membraneless organelles.
These include nucleoli, Cajal bodies, gems, paraspeckles, and PML
bodies in the nucleus and processing (P) bodies, stress granules,
and P granules in the cytoplasm (Zhu and Brangwynne, 2015). Yet,
many questions remain about the physical basis by which these
compartments form and function. One hypothesis that has gained
signiﬁcant attention is that these membraneless organelles form
through phase separation (Brangwynne et al., 2009; Brangwynne,
2013; Hyman et al., 2014; Li et al., 2012). However, precisely what
phase architecture these membraneless organelles adopt has re-
mained the subject of intense scrutiny.
Fig. 1. Associations between human PrLD-containing proteins and the Gene On-
tology categories enriched for them. Columns correspond to the nine GO Slim ca-
tegories enriched for human PrLD-containing proteins (Table 1), and rows corre-
spond to the PrLD-containing proteins; the cell indexed by a given row and column
is colored blue if the corresponding protein is annotated as belonging to the cor-
responding category, and gray otherwise. The rows and columns are hierarchically
clustered based on correlation of GO Slim annotations. The PLAAC COREscore is also
indicated in the far right column using a red color gradient with ranging from black
(score 0) to saturated red (score 64), as indicated by the color bar. Rows and col-
umns are ordered by a correlation-based clustering. The 66 of 240 PrLD-containing
proteins not associated with any of these categories are not shown (the full list of
human proteins with PrLDs is presented in Table S1).
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Early evidence that membraneless organelles may be liquid-
like came from the study of P granules. In the Caenorhabditis ele-
gans embryo, polarization along the anterior-posterior axis leads
to accumulation of P granules in the embryo posterior to mark
germ cells (Seydoux and Braun, 2006; Strome and Lehmann,
2007). Three-dimensional tracking of ﬂuorescently labeled P
granule components revealed that upon symmetry breaking, P
granules form spontaneously in the embryo posterior in the vici-
nity of polarity proteins. Thus, P granule formation is driven by
local decreases in the saturating concentration of P granule com-
ponents in the embryo posterior and an increased ﬂux of P granule
components into the embryo posterior (Brangwynne et al., 2009).
Furthermore, P granules exhibit classic liquid properties such as
fusion, dripping and wetting (Brangwynne et al., 2009, 2015).
Together, these data strongly argued for liquid-liquid phase se-
paration as a mechanism for subcellular cytoplasmic architecture.
A small molecule screen for compounds to promote neuronal
progenitor cell differentiation into mature neurons led to the
serendipitous discovery that biotinylated 5-aryl-isoxazole-3-car-
boxyamide (b-isox) selectively precipitates known protein com-
ponents of ribonucleoprotein (RNP) granules, including TDP-43
and FUS (Kato et al., 2012). In vitro, recombinant full-length FUS
phase transitions to a hydrogel-like state, but very high protein
concentrations are required (Kato et al., 2012; Patel et al., 2015).
Furthermore, it was observed that hydrogels formed by the PrLD of
FUS were capable of retaining soluble FUS PrLD, suggesting that
hydrogel assembly is mediated by homotypic interactions in the
FUS PrLD (Kato et al., 2012). Electron microscopy of FUS PrLD hy-
drogels revealed a composition of amyloid-like ﬁbrils (Kato et al.,
2012). X-ray diffraction analysis showed prominent reﬂections at
4.6–4.7 Å and 10 Å typical of cross-β structure common to amyloid
ﬁbrils, again strongly suggesting an amyloid-like structural basis to
hydrogel architecture (Kato et al., 2012). These hydrogels and ﬁ-
brils were readily dissolved upon exposure to SDS or mild (37 °C)
heating, suggesting that they were distinct and more dynamic
than the SDS-resistant amyloid ﬁbrils formed by yeast prions (Kato
et al., 2012; Kryndushkin et al., 2003; Serio et al., 2000; Shorter
and Lindquist, 2006). This ﬁnding was consistent with previous
work demonstrating that puriﬁed FUS spontaneously assembles
into SDS-soluble ﬁbrils (Sun et al., 2011). However, whether the
hydrogels formed in vitro were reﬂective of RNP granules found in
cells remained uncertain (Weber and Brangwynne, 2012).
Multiple reports have suggested that RNA granules exist as
predominantly liquid compartments and not gel-like compart-
ments in cells (Burke et al., 2015; Lin et al., 2015; Molliex et al.,
2015; Murakami et al., 2015; Patel et al., 2015; Zhang et al., 2015).
For example, in cells and in vitro, FUS forms dynamic assemblies
that are rapidly recruited to sites of DNA damage, and display
physical characteristics of liquid droplets as predicted by classical
physics of polymeric phase transitions, including fast internal dy-
namics, spherical morphology, and a propensity for two droplets
to readily fuse when in close contact with one another (Altmeyer
et al., 2015; Burke et al., 2015; Lin et al., 2015; Murakami et al.,
2015; Patel et al., 2015). Importantly, the PrLD mediates the phase
transition as deletion of the PrLD abrogates droplet assembly.
Detailed study of RBPs hnRNPA1, Lsm4, Tia1, and Pub1 revealed
similar behavior (Burke et al., 2015; Lin et al., 2015; Molliex et al.,
2015). Droplet formation was inﬂuenced by the presence of mo-
lecular crowding agents, ionic strength, and presence of RNA or
other polyanions, such as poly-ADP ribose (Burke et al., 2015; Lin
et al., 2015; Molliex et al., 2015; Murakami et al., 2015; Patel et al.,
2015; Zhang et al., 2015).
The identity of the bound RNA tunes the biophysical properties
of the RNP granule (Zhang et al., 2015). In the ﬁlamentous fungus
Ashbya gossypii, the RBP Whi3 possesses a PrLD that enables as-
sembly into liquid droplets to organize cyclin transcripts (CLN3) at
sites of nuclear division and formin transcripts (BNI1) at polarity
sites where new branch sites are located (Zhang et al., 2015). Mi-
crorheology studies revealed that Whi3 droplets bound to BNI1 are
less viscous than CLN3-bound droplets (Zhang et al., 2015). Ad-
ditionally, BNI1 droplets fuse with one another faster than CLN3
droplets (Zhang et al., 2015). This suggests that client RNA identity
is critical to tuning the biophysical properties of RNP granules, and
that different physical properties of RNP granules may be opti-
mized for speciﬁc cellular functions (Guo and Shorter, 2015; Zhang
et al., 2015). This latter point raises a provocative parallel with
yeast prions, where conformational diversity gives rise to distinct
prion strains with unique phenotypes (King and Diaz-Avalos,
2004; Roberts et al., 2009; Shorter, 2010; Tanaka et al., 2004). It is
possible that bound RNAs may deﬁne ‘strains’ of RNP granules by
tuning their biophysical properties.
The case that biophysical properties of RNP granules reﬂect
their functional role is perhaps most strikingly made in S. cerevi-
siae. Speciﬁcally, whereas P bodies are constitutively active sites
involved in mRNA processing and degradation and exist as liquid
droplets in yeast, stress granules are inactive storage sites for
proteins and RNA that form rapidly upon onset of stress, and are
solid, gel-like aggregates (Balagopal and Parker, 2009; Kroschwald
et al., 2015). Yeast rely on the protein disaggregase and hexameric
AAAþ ATPase, Hsp104 (DeSantis and Shorter, 2012), to maintain
the ﬂuidity of P bodies (Kroschwald et al., 2015). Metazoa lack an
Hsp104 homolog (Erives and Fassler, 2015; Shorter, 2008), and
curiously in mammalian cells P bodies and stress granules exist in
more liquid-like states (Kroschwald et al., 2015). Thus, the pow-
erful disaggregase activity of Hsp104 may enable yeast cells to
readily exploit solid, gel, and liquid states in RNP granules
(Kroschwald et al., 2015).
What structure(s) do the PrLDs of RNA-binding proteins adopt
in liquid droplets? Solution NMR study of the FUS PrLD in
monodisperse solution and condensed into droplets revealed that
the PrLD retains disordered character in droplets (Burke et al.,
2015). This ﬁnding suggests a model in which these liquid droplets
maintain rapid internal dynamics while being held together by
transient intermolecular contacts between adjacent PrLDs (Burke
et al., 2015).
In an attempt to further address this question, a mass spec-
trometry-based chemical footprinting method has been employed
in which N-acetylimidazole (NAI) is used to acetylate serine, tyr-
osine, lysine, threonine, arginine, and asparagine side chains in
proteins (Xiang et al., 2015). Using two model proteins, re-
combinant glutathione-S transferase (GST) and poly-ADP-ribose
polymerase (PARP) isolated from HEK 293T cell nuclei, it was
shown that solvent-accessible side chains (as assessed by available
crystallographic data for these two proteins) are more readily
acetylated (Xiang et al., 2015). Thus, the acetylation pattern or
“footprint” for a given protein can be used as a conformational
proxy (Xiang et al., 2015).
This technique was then deployed to show that the PrLD of
hnRNPA2 in droplets or polymerized into hydrogels in vitro, or
hnRNPA2 isolated from nuclei adopt similar conformations, as
assessed by their NAI footprints (Xiang et al., 2015). This con-
gruence might suggest that cross-β ﬁbrillization underpins both
phase transitions to liquid droplets and hydrogel formation (Xiang
et al., 2015). Curiously, however, hnRNPA2 PrLD fused to maltose
binding protein (MBP) to maintain the hnRNPA2 PrLD in a soluble,
monomeric state also displayed a footprint qualitatively similar to
that obtained for hydrogels, liquid droplets, and ﬁbrils (Xiang et al.,
2015). Therefore, it is difﬁcult to interpret precisely how the
hnRNPA2 chemical footprints relate to hnRNPA2 structure. One
possibility is that the observed NAI footprint in the monomeric
state may be due to contamination by small amounts of ﬁbrils.
This possibility is supported by the fact that the intensity of the
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footprint progressively increased with time after MBP cleavage,
and suggests that the NAI footprinting method detects hnRNPA2
ﬁbril abundance. Alternatively, a fraction of hnRNPA2 PrLDs might
exhibit cross-β structure even in the context of monomeric, so-
luble hnRNPA2. Although the hnRNPA2 PrLD is predicted to be
intrinsically disordered in the soluble, monomeric state (Kim et al.,
2013), circular dichroism studies suggest that this domain may
adopt β-sheet-rich structures in solution (Landsberg et al., 2006).
Another possibility is that similar regions within the hnRNPA2
PrLD may be invariably solvent accessible (or inaccessible) in
distinct structures for monomeric forms in solution, in liquid
phases, and in cross-β ﬁbrils, and consequently the NAI footprint
does not resolve between them. We suggest that further structural
studies using complementary techniques in addition to NAI foot-
printing are needed to further resolve the structure of the
hnRNPA2 PrLD in various soluble, liquid, and ﬁbrillar states.
Parker and colleagues observed that stress granules contain
stable subcompartments that can be isolated in cell lysates, thus
suggesting that stress granules are not simply liquids (Jain et al.,
2016). Instead, they propose that stress granules contain stable,
gel-like cores surrounded by a dynamic liquid shell (Jain et al.,
2016). They demonstrate that the cores of stress granules isolated
from yeast are larger than their counterparts from mammalian
cells, thus reconciling their data with that of Alberti and colleagues
(Kroschwald et al., 2015). The existence of a stable, gel-like core
within stress granules may even provide an explanation for the
observation by McKnight and colleagues that nuclear hnRNPA2
has a similar chemical footprint to recombinant hnRNPA2 poly-
merized into hydrogels (Xiang et al., 2015). However, it remains
unclear whether cross-β polymerization is at the root of the stable
stress granule core (Jain et al., 2016; Xiang et al., 2015). Thus, the
structure of PrLDs within RNP granules is likely to remain the
subject of intense focus in future studies. Moreover, other mem-
braneless organelles, such as the nucleolus, contain distinct sub-
compartments (Boisvert et al., 2007). It will be important to de-
termine whether these are due to separated gel and liquid phases,
or immiscible liquid phases with different viscosities.
4. Membraneless organelles and prion-like domains: a
mechanistic link between normal physiology and
neurodegenerative disease
What is the connection between the functional role of PrLDs in
beneﬁcial phase transitions in the formation of membraneless
organelles and the deleterious misfolding events that these do-
mains undergo in neurodegenerative disease? Recent work in vitro
demonstrates that liquid droplets composed of FUS and hnRNPA1
harboring disease-linked mutations in their PrLDs (FUSG156E and
hnRNPA1D262V) mature to a solid, hydrogel-like state more rapidly
than droplets formed by wild-type protein (Molliex et al., 2015;
Murakami et al., 2015; Patel et al., 2015). Moreover, hydrogel-like
forms of mutant FUS have been speciﬁcally associated with neu-
rodegenerative phenotypes in a C. elegans model of FUS protei-
nopathy (Murakami et al., 2015). Thus, a direct link emerges be-
tween the biophysical propensity of these proteins to adopt more
solid-like structures and neurodegeneration.
Interestingly, the majority of ALS-causing mutations in FUS are
found not in the PrLD but in the C-terminal region (Da Cruz and
Cleveland, 2011; Kwiatkowski et al., 2009; Vance et al., 2009),
where they disrupt a proline-tyrosine (PY) nuclear localization
signal (Lee et al., 2006; Suel et al., 2008; Zhang and Chook, 2012).
Mutations in the FUS PY-NLS lead to persistent cytoplasmic FUS
mislocalization, which correlates with ALS severity (Dormann
et al., 2010), but curiously does not directly increase the biophy-
sical propensity of FUS to aggregate (Sun et al., 2011). However, the
biophysics of membraneless organelle assembly shed new light on
this observation. Membraneless organelles such as nucleoli and P
granules in Caenorhabditis elegans have the property that local
concentration of granular components drive granule droplet con-
densation (Brangwynne et al., 2015; Weber and Brangwynne,
2015; Zhu and Brangwynne, 2015). Thus, a model emerges where
impaired nuclear import of FUS leads to persistent cytoplasmic
FUS droplets that mature to more intractable solid aggregates, in
accordance with ﬁndings in vitro (Lin et al., 2015; Molliex et al.,
2015; Murakami et al., 2015; Patel et al., 2015). Therefore, strate-
gies to boost FUS nuclear import or maintain FUS droplet ﬂuidity
should represent a signiﬁcant therapeutic opportunity for ALS and
FTD.
5. Clearance mechanisms for solid protein aggregates
In S. cerevisiae, the protein-remodeling factor Hsp104 regulates
the formation, elimination, and propagation of beneﬁcial yeast
prions (Sweeny and Shorter, 2008). Hsp104 severs yeast prions to
ensure their dissemination to daughter cells upon division (Sat-
pute-Krishnan et al., 2007; Shorter and Lindquist, 2004, 2006,
2008; Sweeny et al., 2015; Sweeny and Shorter, 2015), and is re-
quired to clear solid stress granules in yeast and to maintain the
ﬂuid integrity of yeast P bodies (Cherkasov et al., 2013; Kroschwald
et al., 2015). Indeed, it is hypothesized that this robust dis-
aggregase machinery coevolved with solid stress granules as a way
for yeast to cope with their vulnerability to environmental ﬂuc-
tuation (Kroschwald et al., 2015). However, metazoa lack a clear
Hsp104 homolog (Erives and Fassler, 2015), and ﬁbrils formed
from human RBPs with PrLDs represent an intractable substrate
for wild-type Hsp104 (Jackrel et al., 2014). Recently, however,
engineered forms of Hsp104 have been generated that potently
suppress the aggregation and toxicity of various disease-linked
RBPs with PrLDs, including TDP-43, FUS, and TAF15 (Jackrel et al.,
2014, 2015; Jackrel and Shorter, 2014a; Sweeny and Shorter, 2015;
Torrente et al., 2016). Moreover, these potentiated Hsp104 variants
dissolve preformed TDP-43, FUS, and TAF15 ﬁbrils in vitro (Jackrel
et al., 2014; Jackrel and Shorter, 2014a). Thus, Hsp104 could re-
present a disruptive technology to enhance metazoan proteostasis
to counter RBP misfolding that causes neurodegenerative disease
such as ALS and FTD (Jackrel and Shorter, 2014b, 2015).
In metazoan cells and yeast, the Hsp110, Hsp70, and Hsp40
protein-disaggregase machinery (Nillegoda and Bukau, 2015;
Shorter, 2011; Torrente and Shorter, 2013), contributes to the
clearance of stress granules (Cherkasov et al., 2013; Kroschwald
et al., 2015; Walters et al., 2015). Hsp70 and Hsp40 chaperones
often get sequestered and inactivated by misfolded protein ag-
gregates (Auluck et al., 2002; Derkatch and Liebman, 2013; Yu
et al., 2014). Thus, enhancement or engineering of this dis-
aggregase machinery might also open potential therapeutic ave-
nues for ALS, FTD, and a variety of other neurodegenerative
disorders.
Deletion of several autophagy-related genes and Cdc48 adaptor
proteins gives rise to constitutive stress granules in S. cerevisiae
(Buchan et al., 2013). Cdc48, or valosin-containing protein (VCP) in
humans, is another hexameric AAAþ ATPase that can promote
autophagy (Ju et al., 2009; Krick et al., 2010; Meyer et al., 2012),
and mutations in VCP cause familial forms of ALS and MSP
(Johnson et al., 2010). These diseases are characterized by the
formation of cytoplasmic protein aggregates containing RBP
components of stress granules (Li et al., 2013). Deletion of the
autophagy gene ATG7 or siRNA-mediated knockdown of VCP leads
to impaired ability to clear stress granules in mammalian cells, and
disease-causing mutations in VCP cause accumulation of con-
stitutive stress granules that contain TDP-43 (Buchan et al., 2013).
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However, it remains unclear whether the sole role of Cdc48/VCP is
to target stress granule components for autophagic degradation or
whether Cdc48/VCP may have also have an active role in dis-
aggregation of stress granules and reactivation of their compo-
nents (Buchan et al., 2013). Indeed, an exciting possibility is that
Cdc48/VCP may represent a triage center for stress granule com-
ponents, effecting the reactivation of salvageable components and
the degradation of others.
6. Concluding remarks
Here, we have reviewed recent advances in our understanding
of prion-like phenomena and architecture across biology, from
epigenetic regulation in the simple model organism S. cerevisiae to
complex mechanisms of eukaryotic subcellular organization. We
suggest that PrDs and PrLDs may have been biologically conserved
for their wide-ranging biological utility. The ability of prions to
rapidly switch between distinct conformational and functional
states confers selective advantages for yeast in the face of en-
vironmental stress (Halfmann et al., 2012; Holmes et al., 2013;
Suzuki et al., 2012; True and Lindquist, 2000; True et al., 2004). In
fungi and metazoa, PrLDs now have a clear functional role in
mediating the reversible coalescence of RNP granules. However, in
humans the persistence and maturation of these RNP granules via
complex mechanisms leads to pathological protein accumulation
and neurodegenerative disease (Fig. 2) (Guo and Shorter, 2015; Lin
et al., 2015; Molliex et al., 2015; Murakami et al., 2015; Patel et al.,
2015; Xiang et al., 2015). We suggest that PrLDs may be general
scaffolds for membraneless subcellular organization. However, this
activity places PrLDs at risk to accessing deleterious misfolding
trajectories that cause neurodegenerative disease (Li et al., 2013).
PrLDs have a very distinctive amino acid composition, but this role
in subcellular compartmentalization via phase transitions and si-
multaneous risk of protein misfolding may extend to other in-
trinsically unfolded, low complexity domains with different amino
acid composition. Regardless, we suggest that deleterious mis-
folding events can be reversed by select protein disaggregases,
which could have important therapeutic applications (Jackrel and
Shorter, 2015; Shorter, 2008; Torrente and Shorter, 2013).
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